<DOC>
	<DOCNO>NCT02688322</DOCNO>
	<brief_summary>Acinetobacter specie emerge agent serious nosocomial infection critically ill patient . Only effective antibiotic currently available treatment pathogen , therefore , sulbactam consider alternative treatment option . The aim study ) reveal population pharmacokinetics ii ) ass probability target attainment ( PTA ) sulbactam septic critically ill patient cause Acinetobacter spp . infection . The study conduct septic critically ill patient cause Acinetobacter spp . Each patient receive 2 g every 12 h sulbactam 10 day , PK study carry day 4 sulbactam therapy Monte Carlo simulation perform determine probability attain specific pharmacodynamic target .</brief_summary>
	<brief_title>Pharmacodynamics Modeling Optimize Dosage Regimens Sulbactam Patients With Acinetobacter Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Acinetobacter Infections</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<criteria>Patient age ≥ 18 year Patients diagnose Acinetobacter infection sensitive sulbactam colistin Infected sterile site Pneumonia define new persistent infiltrate chest radiography associate least one following : purulent sputum , temperature &gt; 38.3°C &lt; 36°C , leukocyte count &gt; 10,000 cell per mm3 , heart rate &gt; 90 beat per min respiratory rate &gt; 20 breath per min Urinary tract infection : Acinetobacter spp ≥ 100,000 cfu/mm3 Patients pregnant . Patients documented hypersensitivity sulbactam colistin Patients chronic renal disease Patients shock</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>sulbactam</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Acinetobacter infection</keyword>
</DOC>